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Abstract
Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. 
aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of 
iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg−1) administered as a single dose 
via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic 
arthritis.
INTROdUCTION
Septic arthritis is an orthopedic emergency leading to poten-
tial joint destruction and associated morbidity and mortality 
[1]. Septic arthritis occurs when micro-organisms infect the 
joint space by direct inoculation or by haematogenous spread. 
Direct introduction of micro-organisms into the joint space 
can result from procedures including intra-articular injection, 
joint aspiration and/or joint surgery. Staphylococcus aureus 
is the most common non-gonococcal aetiology, with over 
25 % of isolates in the United States and in southern/eastern 
Europe having methicillin resistance (methicillin-resistant 
S. aureus, MRSA) [2, 3]. Because of the increasing resistance 
of MRSA to available antimicrobial agents, new ones that are 
efficacious and safe are needed to prevent and treat septic 
arthritis.
Iclaprim, which is in clinical development, is a selective bacte-
rial dihydrofolate reductase inhibitor with potent activity 
against S. aureus in vitro and in clinical trials of acute bacterial 
skin and skin structure infections [4–6]. In a recent surveil-
lance study of patients with skin infections in North America 
and Europe, iclaprim had an MIC90 of 0.12 µg ml−1 for 314 
isolates of MRSA and one of 0.06 µg ml−1 for 304 isolates of 
methicillin-sensitive S. aureus [7].
A murine model was developed to evaluate iclaprim and its 
ability to prevent joint infections caused by S. aureus in mice. 
This is the first study of iclaprim activity in a murine model 
of S. aureus-induced septic arthritis. Iclaprim was studied 
because compared to trimethoprim [the only US Food and 
Drug Administration (FDA)-approved dihydrofolate reduc-
tase inhibitor], it has a lower MIC90 for S. aureus, can be given 
without a sulfonamide, overcomes select trimethoprim resist-
ance and does not cause hyperkalemia, unlike trimethoprim/
sulfamethoxazole, which is frequently used for the treatment 
of septic arthritis.
MeTHOdS
All procedures in this study were in compliance with the 
Protection of Animals Act. This animal experiment complied 
with the National Institutes of Health guide for the care and 
use of laboratory animals [8] and the guidelines were followed 
after review and approval by the Institutional Animal Care 
and Use Committee at the University of Glasgow, Glasgow 
(protocol number 463208). Two experimental groups were 
studied for the activity of iclaprim in S. aureus-induced septic 
arthritis. The first experimental group included a lower infec-
tion inoculum of 5×107 colony-forming units (c.f.u.) ml−1 and 
higher doses of iclaprim (20 and 80 mg kg−1), and followed 
the mice to day 8. The second experimental group studied 
included a higher infection inoculum of 1×108 c.f.u. ml−1 
and lower doses of iclaprim (2.5, 5, 10 and 20 mg kg−1), and 
followed the mice to day 12.
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Antimicrobial agents
Iclaprim powder (Motif BioSciences, Princeton, NJ, USA) 
was used in the in vivo studies after resuspension in sterile 
deionized water. The range of doses of iclaprim (2.5 to 80 mg 
kg−1) have been studied in toxicology studies and are within 
the no-observed-adverse-effect level range of iclaprim admin-
istration to mice (unpublished data). Therefore, this was the 
dose range studied for this study.
Bacterial growth media
Trypicase soy agar (TSA) plates (BBL, Franklin Lakes, NJ, 
USA), brain heart infusion (BHI) broth (BBL, Franklin Lakes, 
NJ, USA) and Cytodex beads (Sigma-Aldrich, St Louis, MO, 
USA) were used. The standard Clinical and Laboratory Stand-
ards Institute (CLSI) broth microdilution technique [9] was 
used to determine the MIC, performed in triplicate, for the 
strains employed in these studies.
Bacterial strains and bacteria culture
S. aureus strain LS-1, which was isolated from a patient with 
septic arthritis and causes septic arthritis in a New Zealand 
white mouse, as previously described, was supplied by 
Professor Curtis Gemmel [9–11]. This strain was sensitive to 
iclaprim (MIC 0.12 µg ml−1) and trimethoprim/sulfamethoxa-
zole (MIC 2 µg ml−1) and resistant to oxacillin (MIC 4 µg ml−1). 
S. aureus LS-1 was grown on TSA plates at 37 °C in 5 % CO2. 
The bacterial inoculum was prepared by resuspending several 
colonies of an overnight streak culture in saline and adjusting 
a 1 : 10 dilution of the suspension to an OD of 0.1 at 625 nm. 
The adjusted suspension was prepared to a final standard-
ized concentration of 5×107 c.f.u. ml−1 for experiment 1 and 
1×108 c.f.u. ml−1 for experiment 2. Bacterial counts were 
performed to determine inoculum size. These inoculum sizes 
were used based on previous published data indicating that 
intravenous injection of 1×107 c.f.u. ml−1 S. aureus LS-1 cells 
has been shown to induce septicaemia that lasts for 24–48 h 
with localization in the joints after approximately 4–5 days 
[9, 12]. Furthermore, bacterial arthritis occurs in a high 
proportion (approximately 75 %) of Swiss mice in this model 
[12].
Animals
Adult male (4–6 weeks old) Swiss white mice (MF1) weighing 
approximately 25 g were acclimated for 5 days prior to the 
first study day. Animals had free access to food and water 
throughout the study.
Infection studies
In both experimental groups (one with a lower infection 
inoculum and the second with a higher infection inoculum), 
0.2 ml of the stock S. aureus LS-1 inoculum was injected by 
intravenous administration into the tail vein because these 
infection inocula have been shown to consistently result 
in septic arthritis in this animal infection model [10, 12]. 
Subsequently, iclaprim (2.5–80 mg kg−1, which is 1–2×MIC) 
or vehicle control was intravenously injected into the tail vein 
within 20–30 min. These single doses (2.5–80 mg kg−1) were 
used based on prior studies showing that these doses result 
in 1 and 2 log10 c.f.u. reductions at 24 h post-treatment in a 
mouse abscess model [13].
After dosing with iclaprim or vehicle control, the mice were 
then examined individually at regular intervals to day 8 in 
experiment 1 and day 12 in experiment 2 and scored for 
morbidity, mortality and development of septic arthritis. The 
assessment of severity of joint involvement of four joints per 
animal was scored on a scale of 1–3, with 1 point for mild 
swelling or erythema or both, 2 points for moderate swelling 
and erythema and 3 points for marked swelling and erythema 
and occasionally ankylosis, as previously published [10, 12]. 
These changes were assessed and scored for each limb and the 
mean score per animal group was taken.
Statistical analysis
Within each experimental group (one with a lower infection 
inoculum and the second with a higher infection inoculum), 
mean values and standard deviations were calculated for each 
dose group. An analysis of variance (ANOVA) was performed 
to determine statistical differences for the incidence of affected 
joints, severity of joint involvement and mortality by day by 
Table 1. Experiment 1: development of septic arthritis and mortality 
rates in mice infected with S. aureus LS-1
Day Parameter S. aureus LS-1-infected mice*
Control 20 mg kg−1 
iclaprim
P-value 80 mg kg−1
iclaprim
P-value
Day 
4
Joints 
affected, 
n/n %
17/32 
(53.1)
6/40 (15.0) <0.01 5/36 (13.9) <0.01
Severity 
score, mean
1.65 1.0 1.0
Mortality, 
n/n
2/10 0/10 1/10
Day 
6
Joints 
affected, 
n/n %
13/32 
(40.6)
10/32 
(31.3)
ns 6/36 (16.7) <0.01
Severity 
score, mean
1.92 1.5 1.36
Mortality, 
n/n
3/10 2/10 1/10
Day 
8
Joints 
affected, 
n/n %
16/28 
(57.1)
15/32 
(46.9)
ns 6/32 (18.8) <0.01
Severity 
score, mean
1.68 1.73 1.33
Mortality, 
n/n
4/10 3/10 2/10
*The assessment of joints affected and he severity score excludes 
mice that expired prior to the day of examination.
NS=not statistically significant.
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dose group or control. A P-value of <0.05 was considered a 
statistically significant difference between the dose groups.
ReSUlTS
In experiment 1 (lower infection inoculum), iclaprim at 
80 mg kg−1 reduced the incidence of septic arthritis (Table 1). 
By day 4, all (100 %; 10/10) of the infected control mice had 
at least one affected joint compared with 55 % (5/9) of mice 
that received 80 mg kg−1 of iclaprim. The decreases on day 
4 in the percentage of joints affected in mice that received 
a single dose of 80 mg kg−1 iclaprim (13.9 %) or 20 mg kg−1 
iclaprim (15.0 %) relative to infected controls (53.1 %) were 
statistically significant and continued to day 8. The severity of 
joint infections was numerically reduced in mice given high-
dose iclaprim, with a mean severity score of 1.33 in animals 
treated with 80 mg kg−1 iclaprim compared with 1.73 and 1.68 
in the low-dose iclaprim and control groups, respectively. The 
survival rates at day 8 were 8/10, 7/10 and 6/10 for mice given 
80 mg kg−1 and 20 mg kg−1 iclaprim and the infected controls, 
respectively.
In experiment 2 (higher infection inoculum), groups of five 
mice were given 0, 2.5, 5, 10, or 20 mg kg−1 of iclaprim with 
improved survival in the iclaprim-treated groups compared 
to the control animals (Table 2). By day 7, 4/6 control animals 
had died, compared to 0/5 in the 20 mg kg−1 iclaprim group 
and 1–2/5 in the mid-dose groups. By the end of the 12-day 
observation period, the survival rate in the 10 and 20 mg kg−1 
groups was 80 % compared to 33 % in the control group. In 
addition, there was a numerically lower incidence of septic 
arthritis among mice treated with iclaprim (10–19 % in treated 
mice compared with 29 % in the infected control) at day 3. 
By day 12, the incidence of septic arthritis and the severity 
scores in the affected joints were similar across the groups, 
but the analysis was confounded by higher mortality rates in 
the untreated and low-dose animals.
dISCUSSION
The development of arthritis and its severity in this murine 
model of S. aureus arthritis have been described [10, 12]. The 
histopathological appearance of the joints of mice inoculated 
with strain LS-1 has been shown to resemble that seen in 
human septic arthritis [10]. The tissue tropism may be due 
to specific binding of S. aureus to bone-specific sialoprotein 
[14]. The S. aureus LS-1 strain also possesses a number of 
genes that govern the expression of soluble virulence factors 
(e.g. alpha and beta haemolysins), which are important for 
the pathogenesis of septic arthritis, and are likely responsible 
in the early onset of septic arthritis.
This is the first reported study to examine the efficacy of 
iclaprim in this murine model of septic arthritis. The devel-
opment of septic arthritis and mortality among the control 
animals (animals that did not receive iclaprim) in both 
experiments 1 (lower infection inoculum) and 2 (higher 
infection inoculum) were consistent with those already 
published [10, 12]. Overall, iclaprim was efficacious in this S. 
aureus joint infection model. Iclaprim is a selective bacterial 
dihydrofolate reductase inhibitor and is bactericidal against 
and suppresses exotoxin production (Panton–Valentine 
leukocidin, alpha-haemolysin and toxic shock syndrome 
toxin 1) in S. aureus [15]. Although iclaprim given intrave-
nously as a single dose did not cure infection, doses as low 
as 10 mg kg−1 were efficacious in reducing septic arthritis and 
improving mortality in infected animals. With the higher 
S. aureus inoculum and lower doses of iclaprim, iclaprim 
was unable to prevent joint infection completely for 12 days, 
although both the incidence and severity of infection were 
greater in the untreated mice compared with those given 
iclaprim. This may be partially explained by the difference 
in the pharmacokinetics of iclaprim when inoculating S. 
aureus followed by administration of iclaprim into the tail 
vein compared to studies of mice infected intraperitoneally 
with S. aureus with iclaprim administered through the mouse 
tail vein [16]. Importantly, iclaprim at doses of 10 and 20 mg 
kg−1 resulted in protection against S. aureus-mediated lethality 
in this experiment. Even in the small groups with the lower 
S. aureus inoculum and higher doses of iclaprim, there was 
evidence that 80 mg kg−1 iclaprim provides some protection, 
given the low rate of mortality and septic arthritis.
These pilot studies had several limitations, including small 
sample sizes. Only a single dose of antibacterial agent was 
given to the mice in both experiments, unlike in the clinical 
setting, where multiple doses would be administered. There-
fore, any protective effect of iclaprim in these experiments is 
likely attributable to the acute lowering of the infective load 
of bacteria for as long as drug levels in vivo are greater than 
the minimal inhibitory concentration/minimal bactericidal 
concentration. Iclaprim is bactericidal with a rapid kill rate 
rather than bacteriostatic, consistent with its activity even in 
this acute setting [6]. No histopathological observation was 
conducted to confirm the severity of the arthritis in this study; 
however, prior studies utilizing this model have validated the 
scoring of joint involvement with histopathological analyses 
[10, 12]. Furthermore, the laboratory that performed this 
study was the same one that performed a prior study with 
the exact same experimental methodology as this animal 
infection model [10]. In addition, there is an increased 
concentration of thymidine in mice (100-fold greater than 
humans), which bypasses the dihydrofolate reductase enzyme, 
antagonizing drug activity and increasing the dose required to 
observe antibacterial effects in rodents; therefore, extrapola-
tion from the doses used in this study to the clinical setting 
is challenging. Further studies are planned using a thymidine 
kinase-deficient S. aureus.
In conclusion, the results from these pilot experiments 
demonstrate that a single dose of iclaprim can reduce the 
incidence of septic arthritis and decrease mortality among 
animals infected with S. aureus.
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